Generation Bio Co. (GBIO)
0.95
0.07 (7.95%)
At close: Jan 15, 2025, 9:41 AM
undefined% (undefined)
| Bid | 0.94 |
| Market Cap | 63.61M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.19 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.96 |
| Volume | 291,898 |
| Avg. Volume (20D) | 327,136 |
| Open | 0.99 |
| Previous Close | 0.88 |
| Day's Range | 0.93 - 1.00 |
| 52-Week Range | 0.75 - 4.65 |
| Beta | undefined |
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 174
Stock Exchange NASDAQ
Ticker Symbol GBIO
Website https://generationbio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 582.56% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Generation Bio Co. is scheduled to release its earnings on Mar 5, 2025,
during market hours.
Analysts project revenue of $2.92M, reflecting a 1.46% YoY growth and earnings per share of -0.23, making a -56.60% decrease YoY.
Analysts project revenue of $2.92M, reflecting a 1.46% YoY growth and earnings per share of -0.23, making a -56.60% decrease YoY.
8 months ago ·
Source
+24.65%
Generation Bio shares are trading higher after the...
Unlock content with
Pro Subscription
